Chimpanzee as model of human benign prostatic hyperplasia

被引:38
作者
Steiner, MS
Couch, RC
Raghow, S
Stauffer, D
机构
[1] Univ Tennessee, Med Ctr, Dept Urol, Urol Res Labs, Memphis, TN 38163 USA
[2] Coulston Fdn, White Sands Res Ctr, Alamogordo, NM USA
关键词
benign prostatic hyperplasia; aging; chimpanzee;
D O I
10.1016/S0022-5347(05)68340-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The etiology and natural history of benign prostatic hyperplasia (BPH), the most common benign disease in aging men, remain obscure. The canine BPH model has serious limitations but other animal BPH models have not been identified. We evaluated whether the chimpanzee, man's closest primate relative, developed spontaneous BPH. Materials and Methods: A cross-sectional analysis of a colony (White Sands Research Center) that contained 700 chimpanzees was undertaken by sampling 63 male and female (controls) chimpanzees 8 to 35 years old. The presence of spontaneous BPH was evaluated by assessing pathological and clinical variables, including prostate volume, serum prostate specific antigen, presence of histological BPH, serum androgens and estradiol, and urodynamics studies. Results: The chimpanzee had evidence of spontaneous histological BPH, and incidence and grade increased with age. Spontaneous BPH was manifested by increased prostate volume, higher serum prostate specific antigen, higher stromal/epithelial ratio and decreased urinary flow rates. As in man, serum androgens did not correlate with BPH in the chimpanzee. Conclusions: Male chimpanzees developed spontaneous histological BPH at the same relative point in their life cycle as humans which resulted clinically in larger prostates and decreased urinary flow rates. Serum hormone levels did not appear to correlate with BPH. A better understanding of the chimpanzee-BPH model may lead to new therapeutic strategies for BPH in man.
引用
收藏
页码:1454 / 1461
页数:8
相关论文
共 50 条
  • [41] Benign Prostatic Hyperplasia and Its Aetiologies
    Briganti, Alberto
    Capitanio, Umberto
    Suardi, Nazareno
    Gallina, Andrea
    Salonia, Andrea
    Bianchi, Marco
    Tutolo, Manuela
    Di Girolamo, Valerio
    Guazzoni, Giorgio
    Rigatti, Patrizio
    Montorsi, Francesco
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (13) : 865 - 871
  • [42] Individualization of treatment in benign prostatic hyperplasia
    Altwein, JE
    EUROPEAN UROLOGY, 1996, 29 : 2 - 6
  • [43] LASER TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    MUSCHTER, R
    HOFSTETTER, A
    UROLOGE-AUSGABE A, 1994, 33 (04): : 281 - 287
  • [44] Optimizing the management of benign prostatic hyperplasia
    Elterman, Dean S.
    Barkin, Jack
    Kaplan, Steven A.
    THERAPEUTIC ADVANCES IN UROLOGY, 2012, 4 (02) : 77 - 83
  • [45] Thermotherapy and thermoablation for benign prostatic hyperplasia
    Gravas, S
    Laguna, P
    de la Rosette, J
    CURRENT OPINION IN UROLOGY, 2003, 13 (01) : 45 - 49
  • [46] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Kuczyk, M. A.
    Herrmann, T. R. W.
    UROLOGE, 2009, 48 (11): : 1365 - 1375
  • [47] Holmium laser for benign prostatic hyperplasia
    Seki, Narihito
    Naito, Seiji
    CURRENT OPINION IN UROLOGY, 2008, 18 (01) : 41 - 45
  • [48] Urtica dioica for benign prostatic hyperplasia
    Posadzki, Pawel
    Kongkaew, Chuenjid
    Ernst, Edzard
    JOURNAL OF HERBAL MEDICINE, 2025, 50
  • [49] Phytotherapy in the treatment of benign prostatic hyperplasia
    Bracher, F
    UROLOGE-AUSGABE A, 1997, 36 (01): : 10 - 17
  • [50] Dutasteride/TamsulosinIn Benign Prostatic Hyperplasia
    Gillian M. Keating
    Drugs & Aging, 2012, 29 : 405 - 419